Compugen Reports Third Quarter 2021 Results
– COM701, Opdivo® and BMS-986207, triple combination dose escalation Phase 1/2 data being presented at 36th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) clears the path to studies in select biomarker informed tumor types – COM902 monotherapy dose escalation Phase 1…
Comments Off on Compugen Reports Third Quarter 2021 Results